Valence 로고
인기
로그인
Loading data for LTGO — first visit, this takes a few seconds.

관심목록에 추가

Latigo Biotherapeutics In...

NasdaqGS: LTGO · 실시간 가격 · USD
22.00
-0.37 (-1.65%)
종가 기준: Aug 25, 2026, 4:21 PM

주가와 핵심 숫자, 최신 뉴스를 한 곳에 모았습니다.

Latigo Biotherapeutics Inc.(LTGO) 주가, 분석 및 데이터

-1.65%

데이터 없음

매수호가22.8
시가총액1.43B
매출 (ttm)n/a
순이익 (ttm)-111.18M
n/a
-2.53
n/a
n/a
P/B (ttm)-0.53
P/S (ttm)n/a
실적 발표일n/a
매도호가22.19
거래량233,864
평균 거래량 (20일)527,818
시가22.62
전일 종가22.37
일중 범위21.49 - 25.00
52주 범위17.22 - 25.00
애널리스트n/a
목표주가n/a
배당n/a
배당락일n/a

LTGO 소개

Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. The company's pipeline includes LTG-001, an oral NaV1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of acute pain; LTG-321, a NaV1.8 inhibitor candidate developed for the treatment of chronic musculoskeletal pain, starting with osteoarthritis; and LTG-418, a NaV1.8 inhibito...

[더 보기]
산업 Biotechnology
섹터 Healthcare
IPO 일자 Aug 7, 2026
직원 수 59
상장 거래소 NasdaqGS
티커 LTGO
웹사이트 https://latigobio.com
전체 기업 정보

재무 실적

2025년 Latigo Biotherapeutics의 매출은 0로, 전년 0 대비 undefined% 증가했습니다. 순이익은 -109.17M로, 78.43% 증가했습니다.

재무제표
news image

1주 전 · 24/7 Wall St.

Inside Latigo Biotherapeutics’ IPO: A Non-Opioid Pain Bet Goes Public

A California biotech just raised $350 million promising to out-perform opioids without the addiction risk, and its auditors were still warning about survival just months ago. Here is what the science ...

news image

2주 전 · Simply Wall St.

Latigo Biotherapeutics (LTGO) On IPO And Trial Data Looks About Right Valued

Latigo Biotherapeutics (LTGO) recently raised US$345.6 million in its IPO, offering 19,200,000 common shares at US$18 each, following publication in the New England Journal of Medicine of clinical dat...